PureTech Health (GB:PRTC) has released an update.
PureTech Health plc, a clinical-stage biotherapeutics company, announces robust financial results for 2023, revealing a considerable cash reserve of $326.0 million and consolidated cash of $327.1 million as of December 31, 2023. The company has a strong operational runway into at least 2027, supporting internal programs, future innovations, and shareholder returns. PureTech’s R&D model delivered value with the $14 billion sale of Karuna to Bristol Myers Squibb and the success of KarXT, a therapy for schizophrenia.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
